Brand-name drug
Ozempic price, strengths & recalls
Brand of semaglutide (generic)
Pharmacies pay $995.82 for 3 mL of Ozempic 1.34 mg/mL, 3 mL pen this week, and from $994.59 to $996.07 across its 6 priced strengths and forms. It is in shortage (being discontinued). It has 54 recalls on record, none ongoing. Its official label last changed on August 19, 2026.
Being discontinuedMedicare price 2027Brand- Fair cash price
- $1,155.69
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Ozempic price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.68 mg/mL, 3 mL pen Brand | $332.02 | $996.07 / 3 mL |
| 1.34 mg/mL, 3 mL pen Brand | $331.94 | $995.82 / 3 mL |
| 2.68 mg/mL, 3 mL pen Brand | $332.00 | $996.01 / 3 mL |
| 1.5 mg tablet Brand | $33.15 | $994.59 / 30 tablets |
| 4 mg tablet Brand | $33.19 | $995.67 / 30 tablets |
| 9 mg tablet Brand | $33.19 | $995.68 / 30 tablets |
The lowest cost per tablet is 1.5 mg tablet at $33.15. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.
Ozempic vs generic semaglutide
There is no generic version of Ozempic on the market yet. Its last listed patent or exclusivity runs to February 1, 2039 - generics often follow, though court cases and settlements can move the date either way.
GenericSemaglutide pricesMedicare negotiated price
Medicare negotiated a maximum fair price of $274.00 for a 30-day supply of Ozempic / Rybelsus / Wegovy, against a 2024 list price of $959.00. It takes effect on January 1, 2027.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
CMS counts Ozempic, Rybelsus and Wegovy as one drug because all three contain semaglutide.
Every Medicare negotiated priceSupply status: shortages & recalls
Shortages
- Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
- Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
- Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 54 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Ozempic
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use RYBELSUS® and OZEMPIC® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets.RYBELSUS (semaglutide) tablets, for oral useOZEMPIC (semaglutide) tablets, for oral useInitial U.S. Approval: 2017
WARNING: RISK OF THYROID C-CELL TUMORS
•
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].
•
RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with RYBELSUS or OZEMPIC tablets [see Contraindications (4), Warnings and Precautions (5.1)].
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
•
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).
•
RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).
Recent major changes (as listed on the label)
Indications and Usage (1) ................................................10/2025
Dosage and Administration (2)...........................................12/2025
Warnings and Precautions
Acute Pancreatitis (5.2)...............................................10/2025
Acute Kidney Injury Due to Volume Depletion (5.5) ...........10/2025
Severe Gastrointestinal Adverse Reactions (5.6) .................10/2025
Acute Gallbladder Disease (5.8).....................................10/2025
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA213051 · Novo
- First approved
- September 20, 2019 (7 years ago)
- Latest approved change
- January 30, 2026
- Approved label
- PDF, Jul 31, 2026
- Generic makers
- None on the market
- Last patent listed
- February 1, 2039
- Exclusivity ends
- October 17, 2028
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Ozempic questions
How much does ozempic cost without insurance?
Pharmacies pay about $995.82 for 3 mL of ozempic 1.34 mg/mL, 3 mL pen ($331.94 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,155.69. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Ozempic?
Yes: semaglutide. Compare semaglutide prices.
Is ozempic in shortage?
Yes. 3 products are listed as in shortage or being discontinued (being discontinued). See which ones.
Has ozempic been recalled?
54 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the ozempic label last change?
The official label was last updated on August 19, 2026 (version 14). See what changed.
Does Medicare have a negotiated price for Ozempic?
Yes: $274.00 for a 30-day supply of Ozempic / Rybelsus / Wegovy, from January 1, 2027. What you pay still depends on your plan.
Talk about ozempic
No comments yet. Questions, tips, what worked for you - start the conversation.